~~<i id='5315991792'><strike id='5315991792'><tt id='5315991792'><pre id='5315991792'></pre></tt></strike></i>~~

Home» Wikipedia» focus

focus

author：comprehensive 2025-09-27 12:02:15 Page View：5

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Kristina Burow of ARCH Venture Partners shares her next big bets STAT
Next article： Virginia high school admissions case could be legal follow

focus

Apple is now the first public company to be valued at $3 trillion

6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

DavidLRyan/TheBostonGlobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourb

What does generative AI mean for health care? We asked experts

MikeReddyforSTATHealthcarecompaniesareracingtoincorporategenerativeAItoolsintotheirproductpipelinesa

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

XenotransplantrecipientRichardSlayman,holdinghandswithhispartnerFaren,poseswithLeonardoRiella(left),